Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04492956 · ClinicalTrials.gov registry record · Phase 2
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
A Phase 2 study of Childhood-Onset Fluency Disorder (Stuttering), sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 9
- Study locations
NCT04492956: Completed Phase 2 study of Childhood-Onset Fluency Disorder (Stuttering), sponsored by Emalex Biosciences.
NCT04492956 is a Phase 2 study of Childhood-Onset Fluency Disorder (Stuttering) that has completed, run by Emalex Biosciences. The registered enrollment target is 68 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04492956, a Phase 2 study of Childhood-Onset Fluency Disorder (Stuttering), has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.
Primary Outcome
Measures stuttering severity in children and adults
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ecopipam
Study Locations (9)
California
- UC Riverside - Riverside
- CI Trials - Santa Ana
Florida
- Clinical Neuroscience Solutions Inc - Jacksonville
- Clinical Neuroscience Solutions Inc - Orlando
Georgia
- Institute For Advanced Medical Research - Atlanta
Kansas
- Social Psychiatry Research Institute - Prairie Village
Michigan
- Michigan State University - East Lansing
New York
- Social Psychiatry Research Institute - Brooklyn
Tennessee
- Clinical Neuroscience Solutions Inc - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 2 |
What the finished NCT04492956 record still lists
NCT04492956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Childhood-Onset Fluency Disorder (Stuttering) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04492956 lists 9 locations in 7 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT04492956 about?
NCT04492956 is a clinical study titled "Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)". This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.
What is the current status of trial NCT04492956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2020-10-02. Estimated completion is 2022-04-04.
What conditions does trial NCT04492956 study?
This clinical trial studies the following conditions: Childhood-Onset Fluency Disorder (Stuttering).
What interventions are being tested in trial NCT04492956?
The interventions under investigation include: Placebo (DRUG), Ecopipam (DRUG).
Who is sponsoring clinical trial NCT04492956?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04492956 being conducted?
This trial has 9 study locations across California, Florida, Georgia, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04492956's enrollment target sits among peer trials
68 967th of 2000 higher than 1,027 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI